Skip to content

Evidence-Based Optimization Research of Yi Qi Wen Yang method in chronic heart failure based on

Evidence-Based Optimization Research of Yi Qi Wen Yang method in chronic heart failure based on

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006075
Enrollment
Unknown
Registered
2022-06-07
Start date
2022-06-13
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

Group1:Yi Qi Wen Yang decoction+"Golden Tiangle"strategy
Group2:"Golden Tiangle"strategy

Sponsors

Jiangsu Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old, gender is not limited; 2. Decreased chronic ejection fraction in accordance with the "China Heart Failure Diagnosis and Treatment Guidelines 2018" (LVEF=40%)Patients with heart failure (HFrEF), NYAH class II-IV, and resting heart rate> 55b.p.m., blood pressure= 90/60mmHg, stable condition can be followed up regularly and monitor heart rate, blood pressure at home; 3. TCM dialectics belong to the heart (qi) yang deficiency, stasis obstructed with water; 4. Voluntarily agree to participate in the trial, and be able to adhere to follow-up and go to the hospital on their own.

Exclusion criteria

Exclusion criteria: 1. Patients with severe hepatic and renal insufficiency, or serious primary diseases of malignant tumors, endocrine, nervous, blood and other systems; 2. Patients with contraindications to the use of ACE/ARB/ARNI, ß receptor blockers, aldosterone antagonists; 3. All factors that can increase the mortality rate: such as cardiogenic shock, malignant arrhythmias, severe valvular disease that has not been surgically repaired, obstructive hypertrophic cardiomyopathy, acute pulmonary edema, pulmonary embolism, severe infection, refractory end-stage heart failure, etc. are not suitable for inclusion; 4. Patients with cognitive impairment or severe psychiatric symptoms; 5. Pregnant or lactating women, as well as those who are allergic to multiple drugs;6.Currently involved in other clinical trials.

Design outcomes

Primary

MeasureTime frame
ß receptor blockers, ACE/ARB/ARNI dosages;

Secondary

MeasureTime frame
TCM Syndrome Points;Cardiac ultrasound;NYHA class;Kansas City Cardiomyopathy Questionnaire;Plasma BNP;

Countries

China

Contacts

Public ContactJIANG Weimin

Jiangsu Provincial Hospital of Traditional Chinese Medicine

jwm0410@njucm.edu.cn+86 13851685249

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026